Literature DB >> 9217519

Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study.

J Battaglia1, S Moss, J Rush, J Kang, R Mendoza, L Leedom, W Dubin, C McGlynn, L Goodman.   

Abstract

Rapid tranquilization is a routinely practiced method of calming agitated psychotic patients by use of neuroleptics, benzodiazepines, or both in combination. Although several studies have examined the efficacy of the three approaches, none have compared these treatments in a prospective, randomized, double-blind, multicenter trial. Ninety-eight psychotic, agitated, and aggressive patients (73 men and 25 women) were prospectively enrolled during an 18-month period in emergency departments in five university or general hospitals. Patients were randomly assigned to receive intramuscular injections of lorazepam (2 mg), haloperidol (5 mg), or both in combination. Patients in each treatment group received 1 to 6 injections of the same study drug within 12 hours, based on clinical need. They were evaluated hourly after the first injection until at least 12 hours after the last. Efficacy was assessed on the Agitated Behavior Scale (ABS), a modified Brief Psychiatric Rating Scale (MBPRS), Clinical Global impressions (CGI) scale, and an Alertness Scale. Effective symptom reduction was achieved in each treatment group with significant (P < .01) mean decreases from baseline at every hourly ABS evaluation. Significant (P < .05) mean differences on the ABS (hour 1) and MBPRS (hours 2 and 3) suggest that tranquilization was most rapid in patients receiving the combination treatment. Study event incidence (side effects) did not differ significantly between treatment groups, although patients receiving haloperidol alone tended to have more extrapyramidal system symptoms. The superior results produced by the combination treatment support the use of lorazepam plus haloperidol as the treatment of choice for acute psychotic agitation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9217519     DOI: 10.1016/s0735-6757(97)90119-4

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  42 in total

1.  Organisational interventions for preventing and minimising aggression directed towards healthcare workers by patients and patient advocates.

Authors:  Evelien Spelten; Brodie Thomas; Peter F O'Meara; Brian J Maguire; Deirdre FitzGerald; Stephen J Begg
Journal:  Cochrane Database Syst Rev       Date:  2020-04-29

2.  Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.

Authors:  Caroline T Nguyen; Michael I MacEntee; Barbara Mintzes; Thomas L Perry
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

3.  Rapid Tranquilization for Psychiatric Patients with Psychomotor Agitation: What is Known About it?

Authors:  Clayton Gonçalves de Almeida; Mariana Del Grossi Moura; Silvio Barberato-Filho; Fernando de Sá Del Fiol; Rogério Heládio Lopes Motta; Cristiane de Cássia Bergamaschi
Journal:  Psychiatr Q       Date:  2017-12

4.  Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine.

Authors: 
Journal:  BMJ       Date:  2003-09-27

Review 5.  Pharmacological management of agitation in emergency settings.

Authors:  A Yildiz; G S Sachs; A Turgay
Journal:  Emerg Med J       Date:  2003-07       Impact factor: 2.740

6.  Level of agitation of psychiatric patients presenting to an emergency department.

Authors:  Leslie S Zun; La Vonne A Downey
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

7.  New treatments for agitation.

Authors:  Leslie Citrome
Journal:  Psychiatr Q       Date:  2004

Review 8.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 9.  2C or not 2C: phenethylamine designer drug review.

Authors:  Be Vang Dean; Samuel J Stellpflug; Aaron M Burnett; Kristin M Engebretsen
Journal:  J Med Toxicol       Date:  2013-06

Review 10.  Benzodiazepines for schizophrenia.

Authors:  Markus Dold; Chunbo Li; Magdolna Tardy; Vesal Khorsand; Donna Gillies; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.